Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.51 |
| ▸ | GFRA2 | O00451 | 1/20 | 0.48 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12019229 | 0.87 | FFAR1 (0.59) | FFAR1MEN1KMT2ADRD3MAPT | |
| SCHEMBL12019230 | 0.80 | FFAR1 (0.61) | FFAR1MEN1KMT2APOLB | |
| SCHEMBL1513399 | 0.80 | FFAR1 (0.45) | FFAR1MEN1KMT2AMAPT | |
| SCHEMBL12017998 | 0.79 | FFAR1 (0.47) | FFAR1GFRA2GFRA3KMT2A | |
| SCHEMBL1746725 | 0.78 | GFRA3 (0.50) | FFAR1GFRA2GFRA3MAPTPOLB | |
| SCHEMBL11343724 | 0.78 | KMT2A (0.49) | MEN1KMT2APOLBATM | |
| SCHEMBL24470813 | 0.78 | PTGS2 (0.61) | FFAR1MAPTPOLB | |
| SCHEMBL29713112 | 0.78 | PTGS2 (0.61) | FFAR1MAPTPOLB | |
| SCHEMBL931742 | 0.76 | MAOA (0.52) | MEN1KMT2AATMOPRK1 | |
| SCHEMBL930973 | 0.76 | MAOA (0.49) | MEN1KMT2AMAPTATMF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | FFAR1 39/4885GFRA2 748/4885GFRA3 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.